Keyphrases
Inflammation
100%
Human Immunodeficiency Virus Infection
100%
IL-6 Blockade
100%
Tocilizumab
100%
C-reactive Protein
22%
Placebo
22%
Interleukin-6
22%
Antiretroviral Therapy
22%
Lipid Levels
22%
Cell Cycling
22%
T Cells
11%
Cardiovascular Risk
11%
CD4+ T
11%
Comorbidity
11%
Lipids
11%
Clinical Significance
11%
Placebo-controlled
11%
AIDS/HIV
11%
Treatment Duration
11%
Inflammatory Markers
11%
TNF Receptor 1 (TNFR1)
11%
Neutropenia
11%
Treatment Toxicity
11%
Interleukin-6 Levels
11%
Index Level
11%
D-dimer
11%
Clinical Trial Registry
11%
Intent-to-treat Analysis
11%
Soluble CD14 (sCD14)
11%
Lipid Classes
11%
Inflammatory Index
11%
Inflammatory Environment
11%
Naïve CD4+ T Cells
11%
Pharmacology, Toxicology and Pharmaceutical Science
Human Immunodeficiency Virus Infection
100%
Inflammation
100%
Interleukin 6
100%
Tocilizumab
100%
Placebo
33%
C Reactive Protein
22%
Clinical Trial
11%
HIV
11%
Receptor
11%
Cytokine
11%
Neutropenia
11%
Tumor Necrosis Factor Receptor
11%
D Dimer
11%
Comorbidity
11%
Cardiovascular Disease
11%
Medicine and Dentistry
Human Immunodeficiency Virus Infection
100%
Interleukin 6
100%
Tocilizumab
100%
Placebo
33%
C Reactive Protein
22%
T-Helper Cell
22%
Antiretroviral Therapy
22%
Clinical Trial
11%
Cardiovascular Disease
11%
T Cell
11%
Human Immunodeficiency Virus
11%
Receptor
11%
Cytokine
11%
Maturation
11%
Clinical Significance
11%
Effect Size
11%
Intention-to-Treat Analysis
11%
Tumor Necrosis Factor Receptor
11%
Neutropenia
11%
D-Dimer
11%
Comorbidity
11%
Immunology and Microbiology
Human Immunodeficiency Virus Infection
100%
Interleukin 6
100%
Tocilizumab
100%
T-Helper Cell
22%
C-Reactive Protein
22%
Lipid Level
22%
Blood Plasma
11%
T Cell
11%
Human Immunodeficiency Virus
11%
Cytokine
11%
Maturation
11%
Tumor Necrosis Factor Receptor
11%
CD14
11%
Comorbidity
11%